Although the number of percutaneous coronary interventions (PCI) has declined in many countries, 955,000 procedures were still done in the United States in 2010.[@bib0065] In some countries, such as India and Brazil, the procedure count is still rising.[@bib0070], [@bib0075] Also, in-hospital mortality and complications could occur in up to 1.31% and 11.5% of patients, respectively.[@bib0065], [@bib0080] The prevalence of myocardial necrosis after PCI varies according to the criteria and biomarkers used for diagnosis. Troponin I (TnI) elevation has been found in 16--73% of patients, and is associated with an increase in mortality as high as 45%, according to multiple meta-analyses.[@bib0085], [@bib0090], [@bib0095] Additionally, 20% of these patients have a cardiovascular event during hospitalization, further illustrating the prognostic value of this endpoint.[@bib0090] Levels above 5 times the 99th percentile predict an even worse outcome, and similar findings involving high-sensitivity (HS) assays have also been described.[@bib0100]

Clinical, angiographic and procedure related conditions have been shown to be predictors of enzyme elevation after PCI. Older age, diabetes mellitus, heart failure, anemia, renal insufficiency, baseline elevated TnI, peripheral atherosclerosis, multivessel disease, multistenting, bifurcation lesions, calcified arteries and intraluminal thrombi are significant known risk factors.[@bib0105], [@bib0110] The purpose of this study was to measure the prevalence of TnI elevation after elective PCI and to determine new potential risk factors associated with this outcome.

Consecutive patients submitted to PCI were screened between January 2013 and December 2014 in a private hospital in Rio de Janeiro, Brazil. Clinical, angiographic and procedural characteristics were collected retrospectively by chart review. Only elective procedures were included, and were defined by absence of myocardial infarction (MI) in the preceding 2 weeks to the intervention. Patients hospitalized for more than 7 days before the procedure and those with sepsis or active cancer were also excluded. Coronary obstructions ≥70% were considered relevant to determine the number of diseased vessels. Only those with at least 1 TnI (Abbot Laboratories, Architect STAT Troponin I or Architect High Sensitive STAT Troponin I) measured between 6 and 24 h post-PCI were included. Levels above the 99th percentile were considered elevated, and were defined differently for men (\>0.033 ng/ml or \>34.2 pg/ml for HS TnI) and women (\>0.013 ng/ml or \>15.6 pg/ml for HS TnI). In accordance with the Declaration of Helsinki, the study was approved by the hospital\'s human research committee and informed consent was not considered necessary.

Stata^®^ 11.0 was used for statistical analysis. Collected data were correlated with any or ≥5 times the 99th percentile TnI elevations. Categorical variables were analyzed with Pearson\'s *χ*^2^ and Fisher\'s exact tests. Continuous variables were assessed by 2-sample *t* tests and the Wilcoxon-Mann--Whitney test. Variables with a *p* value \<0.1 in the univariate analysis were included in the multivariate model. A *p* value \<0.05 was considered significant.

A total of 158 patient-procedures were screened for inclusion, of which 46 were excluded because of recent MI (30), absence of post-procedural TnI levels (7), prolonged hospitalization (4), sepsis (3) or active cancer (2), leaving 112 procedures that were included in the analysis. Eighteen patients had 2 procedures and one patient had 3 during the study period, so the interventions were performed in 92 individual patients. Besides aspirin, a clopidogrel loading dose between 300 and 600 mg was routinely administered during or immediately after the intervention, even to those previously using the medication.

Troponin elevation occurred in 62.5% of the procedures and 68.5% of patients. Clinical, angiographic and procedural characteristics and their relationship to TnI elevation are listed in [Table 1](#tbl0005){ref-type="table"}. Among the 19 patients with multiple procedures, 16 (84.2%) had at least one intervention with enzyme elevation, although the prevalence within the 39 procedures performed in this group was 58.9%. Greater than 5 times TnI increase occurred in 32.1% of the interventions.Table 1Clinical, angiographic and procedural characteristics according to TnI elevation.Table 1Patient characteristicsTotal (%)TnI \> 99th percentile (%)TnI ≤ 99th percentile (%)*p* valueTotal patient-procedures11270 (62.5)42 (37.5)--Mean age, yrs (SD±)70.7 (11.3)72.9 (11.3)67.0 (10.6)**0.008**Male97 (86.6)8097.6**0.009**College education70 (62.5)58.669.00.268Hypertension103 (92)92.990.50.726Diabetes40 (35.7)32.940.50.415Hyperlipidemia98 (87.5)87.188.11.0Body mass index ≥30 kg/m^2^26 (23.2)24.321.40.729Heart failure or LVD18 (16)209.50.188Mean hemoglobin, mg/dl (SD±)13.1 (1.46)12.8 (1.58)13.5 (1.12)**0.017**Mean creatinine, mg/dl (SD±)1.14 (0.5)1.15 (0.47)1.13 (0.56)0.832Current or prior tobacco use37 (33)32.933.30.959Prior MI or symptomatic CAD82 (73.2)7078.60.321Prior PCI56 (50)45.757.10.242Prior CABG23 (20.5)21.419.00.763Pre-procedural medications[a](#tblfn0005){ref-type="table-fn"} Aspirin82 (73.2)67.183.30.08 Clopidogrel50 (44.6)42.947.60.624 β-Blockers50 (44.6)45.742.90.768 ACEi or ARB63 (56.3)67.138.1**0.003** CCB32 (28.6)32.921.40.195 Statins82 (73.2)72.973.80.912Angiographic and procedural aspects Multivessel disease[b](#tblfn0010){ref-type="table-fn"}45 (40.2)44.333.30.252  2 Vessels29 (25.9)----  3 Vessels16 (14.3)---- Multivessel angioplasty[c](#tblfn0015){ref-type="table-fn"}25 (28)31.414.3**0.046** Multistenting[d](#tblfn0020){ref-type="table-fn"}45 (40.2)45.7310.123High-Sensitivity TnI Measurement33 (29.5)31.426.20.556Mean TnI Levels, ng/ml (SD±)0.84 (3.1)1.31 (3.8)0.05 (0.1)**0.036**[^1][^2][^3][^4][^5][^6]

Age, female sex, low pre-procedural hemoglobin, prior angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use and multivessel angioplasty were related to any TnI elevation. When considering elevations ≥5 times, only age did not remain statistically significant, while previous aspirin use had a protective effect ([Table 2](#tbl0010){ref-type="table"}). In the multivariate analysis, age ≥70 years, ACEi or ARB use, multivessel angioplasty, and absence of previous aspirin use appeared as significant risk factors for any TnI increase, whereas only female sex, pre-procedural hemoglobin \<13 mg/dl and multivessel PCI predicted ≥5 times elevations. Also, patients with a college education had a significantly lower mean post-PCI TnI level (0.36 ng/ml SD± 0.72 vs 1.64 ng/ml SD± 4.9, *p* = 0.03). The use of HS TnI did not predict enzyme elevation.Table 2Multivariate predictors of troponin elevation ≥5 times above the 99th percentile.Table 2PredictorUnivariate OR (95% CI)*p* valueMultivariate OR (95% CI)*p* valueFemale sex3.89 (1.26--12.0)0.0184.17 (1.08--16.16)**0.039**Hemoglobin \<13 mg/dl2.89 (1.24--6.77)0.0143.1 (1.17--8.2)**0.022**Prior aspirin use[a](#tblfn0025){ref-type="table-fn"}0.42 (0.18--0.99)0.0490.39 (0.14--1.1)0.074ACEi or ARB use2.27 (0.98--5.26)0.0552.67 (0.98--7.28)0.055Multivessel angioplasty[b](#tblfn0030){ref-type="table-fn"}2.82 (1.16--6.84)0.0223.22 (1.16--8.93)**0.025**[^7][^8][^9][^10]

Our study demonstrated a high prevalence of TnI elevation, although still comparable to other publications. The findings that older age, female sex, pre-procedural hemoglobin and multivessel intervention are predictors of enzyme increase are also compatible with other studies.[@bib0105], [@bib0110] Aspirin and college education had a protective effect, which is in accordance to Khawaja et al\'s findings of a worse prognosis after PCI in patients without at least a high school education.[@bib0115] The association of prior ACEi use with TnI elevation has been previously described in a rat model by Mustafa et al., and could be explained by a greater enzyme washout after the artery is opened due to local vasodilation.[@bib0120] Other hypotheses include an interference in the TnI assay or its metabolization, or even a greater medication usage among those with heart failure (72.2% × 53.2%), which could act as a confounder.

Troponin increase after elective PCI is a useful surrogate for future adverse clinical events, as numerous publications have shown. These harmful outcomes may result not only from myocardial injury, but also from coronary wall damage and subsequent endothelial dysfunction. Determining the main factors associated with this endpoint is an essential step in improving patient care and prognosis. Our data hypothesize on new possible associations, such as previous ACEi or ARB use and educational status, as well as the potentially protective effect of aspirin, although potential confounders could still have influenced these findings. In conclusion, PCI is not a risk free procedure and these results underscore the importance of a careful clinical assessment before its utilization.
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[^1]: TnI -- troponin I; MI -- myocardial infarction; LVD -- left ventricular dysfunction; CAD -- coronary artery disease; PCI -- percutaneous coronary intervention; CABG -- coronary artery bypass grafting; ACEi -- angiotensin converting enzyme inhibitors; ARB -- angiotesin receptor blockers; CCB -- calcium channel blockers.

[^2]: Bold values are \<0.05.

[^3]: Medication usage at hospital admission.

[^4]: ≥70% obstruction in ≥2 vessels.

[^5]: Intervention in ≥2 vessels.

[^6]: Implantation of ≥2 stents.

[^7]: OR -- odds ratio; CI -- confidence interval; ACEi -- angiotensin converting enzyme inhibitors; ARB -- angiotesin receptor blockers.

[^8]: Bold values are \<0.05.

[^9]: Usage at hospital admission.

[^10]: Intervention in ≥2 vessels.
